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Abstract
Background: Heterogeneity in B-type natriuretic peptide (BNP) levels, especially among
individuals with acute heart failure with normal left ventricular ejection fraction (HFNEF), can cause
confusion in interpreting results. We investigated the characteristics of cases of acute HFNEF with
only modestly elevated BNP.
Methods: One hundred forty-two patients with acute or acute exacerbation of chronic HFNEF
were divided into two groups by BNP level: BNP < 100 pg/ml (NB group, n = 45) and BNP ≥ 100
pg/ml (B group, n = 97). We compared clinical findings, echocardiography results, and
neurohormonal factors between these two groups.
Results: In the NB group, a history of open-heart surgery (OHS) was more frequent (71% vs. 22%,
p < 0.0001) and hypertension was less frequent (p = 0.0005). Left atrial diameter (LAd) was higher
(p = 0.0026), while interventricular septal thickness, posterior wall thickness, relative wall
thickness, left ventricular mass index were lower (p = 0.0005, p = 0.0225, p = 0.0114, p = 0.0051,
respectively) in the NB group. In patients with HFNEF, a history of OHS remained an independent
predictor of BNP level (< 100 pg/ml) after adjustment for hypertension, age, LAd, and
interventricular septal thickness (odds ratio 3.6, p = 0.0252).
Conclusion: We found associations between acute HFNEF with less elevated BNP and a history
of OHS. In a patient suspected of HFNEF, a history of OHS is considered diagnostic evidence of
presence of diastolic heart failure when plasma levels of BNP are less elevated.
Background
Heart failure with normal left ventricular ejection fraction
(HFNEF), also called heart failure with normal systolic
function or diastolic heart failure, accounts for 40–50% of
cases of heart failure. This condition is commonly
observed in elderly women, particularly those with a his-
tory of hypertension, left ventricular hypertrophy, or dia-
betes mellitus. Congestive symptoms, although generally
milder, do not differ from those in systolic heart failure
(SHF), in which ejection fraction is reduced. Although
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nosis than SHF, the mortality rate for HFNEF and SHF are
nearly equivalent in the elderly. Diagnosis of HFNEF must
be made quickly to enable appropriate treatment, but this
is often difficult, particularly in elderly patients who have
comorbidities such as chronic lung or heart disease. B-
type natriuretic peptide (BNP) level is a useful marker not
only in the diagnosis and determination of the severity of
heart failure, but also in the assessment of treatment
effects [1-4]. However, there is marked heterogeneity in
BNP levels among subjects with heart failure. Although a
BNP level of approximately 100 pg/mL is regarded as a cri-
terion for the diagnosis of heart failure, the interpretation
of BNP level with regard to HFNEF is unclear [5-8]. BNP
level has recently been reported to be also elevated in con-
ditions other than heart disease, such as sepsis and sub-
arachnoid hemorrhage, and to be affected by factors such
as tachycardia, thyroid hormone, glucocorticoid,
endothelin, angiotensin II, and renal function [9]. Under-
standing of extracardiac factors affecting BNP level is cru-
cial when BNP level is used for differentiating heart
disease. On the other hand, BNP level does not increase in
heart failure resulting from tamponade or constrictive
pericarditis [10,11]. In addition, because BNP level gener-
ally tends to be lower in HFNEF compared to SHF [12,13],
the effects of extramyocardial factors must be considered
in the development of HFNEF. In this study, we investi-
gated the characteristics of cases of HFNEF with only mod-
estly elevated BNP during the acute phase.
Methods
Study sample
One hundred and forty-two cases of acute or acute exacer-
bation of chronic HFNEF seen in our department between
2003 and 2006 were studied. The present study was a
cross-sectional observational study in which the diagnosis
of heart failure was based on the Framingham Criteria
[14]. In all cases, more than one cardiologist was asked to
agree on the diagnosis and severity according to the Fram-
ingham Criteria and the New York Heart Association
class. This investigation is in conformity with the princi-
ples outlined in the Declaration of Helsinki and was
approved by the Ethical Committee of Tokyo Women's
Medical University; all subjects gave their informed con-
sent.
The determination of HFNEF was made from symptoms,
signs, chest x-ray results, and ultrasonic echocardiography
(UCG) criteria (ejection fraction ≥ 50%, abnormal ratio of
early diastolic flow velocity to peak late atrial diastolic
flow velocity, and deceleration time of peak early filling
velocity) within 24 hr of congestive heart failure event.
Patients were divided into two groups with respect to BNP
levels: BNP < 100 pg/ml (NB group, n = 45) and BNP ≥
100 pg/ml (B group, n = 97). Patients with acute or severe
mitral or aortic valvular dysfunction, myocardial infarc-
tion and obvious pulmonary disease were excluded. Car-
diac abnormalities in this study included the following
conditions: hypertension, diabetes mellitus, atrial fibrilla-
tion (AF), hypertrophic cardiomyopathy, and mild to
moderate valvular disease. We compared clinical findings,
history of open-heart surgery (OHS), hypertension, diabe-
tes mellitus, and dyslipidemia, chest radiograph and ECG
findings, parameters from echocardiography, frequency
of atrial fibrillation (AF) and moderate or severe tricuspid
valve regurgitation (TR), neurohormonal factors and
other prognostic factors such as serum creatinine, hemo-
globin and serum sodium between the two groups.
In some cases, maximal thickness of the pericardium was
assessed by computed tomography (B group, n = 58, NB
group, n = 24). Measurement were performed without
zooming the pictures, using an electronic caliper that was
placed where the pericardium was clearly visible and with
lesser variations in thickness, namely on the anterior sur-
face of the heart in front of the right and left ventricles.
Blood sampling
Venous blood samples were obtained after 30 min of
supine rest on admission for radioimmunoassay measure-
ment of B-type natriuretic peptide (BNP), A-type natriu-
retic peptide (ANP), plasma norepinephrine, and plasma
aldosterone concentration (PAC) levels. BNP level was
measured by standard radioimmunoassay (Shionoria
BNP kit; Shionogi Co., Osaka, Japan) within 24 hours.
Values of BNP < 43 pg/ml were considered normal.
Echocardiography
All subjects underwent standard two-dimensional
echocardiography with a commercially available system
(Sonos 5500, Philips Medical Systems, Best, The Nether-
lands and Vivid 7, GE Medical System, Horton, Norway)
using a multi-frequency MHz transducer. Cardiac func-
tion was evaluated by M-mode echocardiography guided
by two-dimensional imaging; left atrial diameters (LAd),
interventricular septal thickness (IVST), posterior wall
thickness (PWT), left ventricular end-diastolic diameters
(LVDd), end-systolic diameters (LVDs), and ejection frac-
tion (EF) were measured. The ratio of peak early diastolic
flow velocity to peak late atrial diastolic flow velocity (E/
A), deceleration time of peak early filling velocity (Dct),
and right ventricular systolic pressure (RVSP) were meas-
ured by Doppler imaging. Left ventricular mass index
(LVMI) was measured using the method of Simone et al.
[14], while relative wall thickness (RWT) was measured
using the method of Daniels et al. [15,16].
In addition, as a sub-analysis, patients with a history of
OHS were subdivided into B and NB group for compari-Page 2 of 8
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TR and history of hypertension.
Statistical analysis
Continuous variables are expressed as mean ± SD and
median value. For the relationship between UCG param-
eters, neurohormone levels, blood pressure, heart rate,
age, and other prognostic factors, Mann-Whitney's U test
was performed. Differences between groups described by
categorical variables were analyzed by the chi-square test
for independence or Fisher's exact probability.
The independent diagnostic value of HFNEF without ele-
vated BNP was assessed in multivariate logistic regression
model for all variables that proved to be significant by
univariate analysis in patients with elevated BNP and
those with less elevated BNP. The following dichotomous
or continuous variables were evaluated in the multivariate
model: medical history of OHS and hypertension, LAd,
IVST, age, and PAC. All p values less than 0.05 are
regarded as having statistical significance.
Results
Clinical and Neurohormonal Characteristics
Table 1 summarizes medical therapy, clinical findings,
chest radiograph and ECG findings, biochemical profiles
and pericardial thickness subdivided according to the
BNP levels. The subjects were 77 men and 65 women, ages
73.7 ± 9.9 years old (range, 33 – 93 years old). The B
group (age, 74.8 ± 10.4 years old) was significantly older
(p = 0.0054) than the NB group (age, 71.4 ± 8.3 years
old). Although hypertension was more common (p =
0.0005) in the B group, no differences were observed for
diabetes and dyslipidemia. According to the New York
Heart Association classification, the severity of heart fail-
ure was class II in 113 patients and class III in 29 patients,
with no intergroup differences. As for treatment drugs, the
B group received significantly more angiotensin-convert-
ing enzyme inhibitors and angiotensin II receptor block-
ers, while the NB group received significantly more
digitalis, diuretic drugs, and warfarin (Table 1).
The rate of exertional breathlessness was high and extra-
sounds were low in both groups, with no significant dif-
ferences. However, the NB group had higher rates of
general malaise (p = 0.0018) and hepatomegaly (p =
0.0244). The NB group also had a higher rate of history of
OHS (71% vs. 22%; p < 0.0001), with a mean postopera-
tive period of 21.1 years. The B group had a mean postop-
erative period of 19.7 years, demonstrating no significant
differences from the NB group. In the NB group (n = 31),
surgery involved mitral valve replacement (MVR; n = 13),
mitral valve plasty (n = 1), double valve replacement
(DVR) [mitral valve replacement + aortic valve replace-
ment (MVR+AVR)] (n = 9), open mitral commissurotomy
(OMC) (n = 6), and coronary artery bypass graft (CABG;
n = 2). In the B group (n = 21), surgery involved MVR (n
= 8), AVR (n = 3), DVR (MVR+AVR; n = 2), OMC (n = 1),
atrial septal defect (ASD; n = 3), and CABG (n = 4). Espe-
cially, the NB group also had a higher rate of mitral pros-
thesis (49% vs. 10%; p < 0.0001),
No differences were observed for frequencies of high volt-
age, ST segment abnormality, intraventricular conduction
delay, and AF on electrocardiography. Although cardiot-
horacic ratio on chest radiograph was greater in the NB
group, no differences were observed for the frequencies of
pulmonary congestion and pleural effusion. No inter-
group differences were observed for mean heart rate and
systolic and diastolic blood pressures on admission. The
pericardial thickness in NB group tended to be thicker
than that in NB group (2.4 ± 1.1 mm for B group versus
2.9 ± 1.9 mm for NB group, p = 0.5886). No clear calcified
lesions were observed on computed tomography in
patients with HFNEF with less elevated BNP. The NB
group had a significantly lower ANP level (p < 0.0001)
and a significantly higher PAC level (p < 0.0001). The B
group with a history of OHS had a significantly lower BNP
level than that without a history of OHS (p = 0.0019)(Fig-
ure 1).
Echocardiographic findings
The echocardiographic parameters are shown in Table 2.
No significant intergroup differences were observed for
EF, LVDd, LVDs, RVSP and frequency of TR. The median
values of IVST, PWT, LVMI and RWT were significantly
higher in B group compared to NB group (p = 0.0005, p =
0.0225, p = 0.0051, p = 0.0114, respectively), indicating
greater degree of LV hypertrophy in the B group. The NB
group had a larger LAd (p = 0.0026) (Figure 2). Patients in
the NB group who had a history of OHS also had marked
left atrial enlargement (Figure 2). There was no significant
difference in the frequency of moderate or severe TR
between the two groups.
Sub-analysis of the OHS group
In the group with a history of OHS, the NB group had a
larger LAd than the B group (p = 0.0069) (Figure 2). No
significant differences were observed for left ventricular
dimension, wall thickness, EF, LVMI and frequency of AF.
However, the B group with had a higher frequency of
hypertension than the NB group (p = 0.0093) (data not
shown).
Multivariate logistic regression analysis
Regarding logistic regression analysis, history of OHS,
hypertension, IVST, LAd, age, and PAC were shown to be
significant in univariate analysis, while only a history of
OHS was shown to be significant in multivariate analysis
(Table 3). The model showed that a history of OHS wasPage 3 of 8
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BNP.
Discussion
The present findings suggest a relationship between
HFNEF with less elevated BNP and history of OHS. Fur-
thermore, in the B group, patients who had a history of
OHS had a significantly lower BNP level. HFNEF with less
elevated BNP was associated with a lower rate of history of
hypertension as well as low values for left ventricular
hypertrophy parameters. Patients in the NB group who
had a history of OHS had marked left atrial enlargement,
Table 1: Clinical and neurohormonal characteristics of the patients.
B group NB group p
n 97 45
Age (median) (yrs) 74.8 ± 10.4 (77) 71.4 ± 8.3 (72) 0.0054*
Gender male n (%) 56 (58) 21 (47) 0.2186
Body mass index (kg/m2) 22.1 ± 3.7 (22.2) 20.8 ± 3.6 (20.7) 0.0796
Open-heart surgery n (%) 21 (22) 32 (71) < 0.0001
Mitral prosthesis n (%) 10 (10) 22 (49) < 0.0001
Postoperative period (median) (yrs) 19.7 ± 11.0 (19) 21.1 ± 9.3 (21) 0.6290*
Hypertension n (%) 56 (58) 12 (27) 0.0005
Diabetes mellitus n (%) 25 (26) 12 (27) 0.9103
Dyslipidemia n (%) 22 (23) 4 (8) 0.0617
AngiotensinII receptor blockers/angiotensin- converting enzyme inhibitors n (%) 74 (76) 24 (53) 0.0067
Digitalis n (%) 21 (23) 23 (55) 0.0004
Calcium channel blockers n (%) 32 (36) 12 (29) 0.4245
β blockers n (%) 35 (39) 9 (21) 0.0426
Warfarin n (%) 37 (42) 29 (69) 0.0030
Diuretics n (%) 55 (61) 37 (88) 0.0020
Spironolactone n (%) 34 (38) 26 (62) 0.0094
NYHA II n 77 36 0.9321
III n 20 9
Dyspnea n (%) 84 (88) 40 (91) 0.7752
General malaise n (%) 9 (9) 14 (31) 0.0018
Extra sound n (%) 8 (9) 1 (2) 0.2711
LV distension n (%) 33 (41) 22 (54) 0.1948
Hepatomegaly n (%) 32 (33) 24 (53) 0.0244
Peripheral edema n (%) 50 (52) 21 (47) 0.5486
Systolic blood pressure (median) (mmHg) 136.2 ± 23.6 (134.0) 134.4 ± 17.2 (132.0) 0.6778*
Diastolic blood pressure (median) (mmHg) 74.2 ± 14.8 (72.0) 72.3 ± 13.2 (70.0) 0.2300*
Heart rate (median) (bpm) 81.3 ± 66.5 (72.0) 74.4 ± 17.0 (72.0) 0.6566*
ANP (median) (pg/ml) 122.5 ± 185.4 (82.0) 29.0 ± 59.6 (15.0) < 0.0001*
BNP (median) (pg/ml) 380.7 ± 259.1 (318.0) 59.7 ± 27.1 (60.8)
Plasma aldosterone (median) (ng/dl) 6.9 ± 5.7 (5.0) 17.6 ± 24.1 (10.8) < 0.0001*
Plasma norepinephrine (median) (ng/ml) 0.45 ± 0.29 (0.40) 0.38 ± 0.20 (0.36) 0.4405*
Serum creatinine (median) (mg/dl) 1.07 ± 0.46 (0.94) 0.96 ± 0.48 (0.90) 0.2460*
Hemoglobin (median) (g/dl) 11.9 ± 2.1 (12.1) 11.8 ± 2.1 (12.3) 0.9163*
Serum sodium (median) (mEq/L) 140.2 ± 3.9 (141.0) 140.1 ± 8.6 (140.0) 0.1607*
Chest radiograph:
Cardiothoracic ratio (%) 61.2 ± 10.0 66.0 ± 14.3 0.0484*
Congestion n (%) 23 (26) 3 (12) 0.1826
Effusion n (%) 44 (50) 23 (58) 0.4303
ECG:
High voltage n (%) 10 (14) 4 (14) > 0.9999
ST change n (%) 34 (48) 13 (43) 0.6750
Intraventricular conduction disturbance
n (%) 18 (21) 10 (28) 0.4366
Atrial fibrillation n (%) 47 (57) 29 (73) 0.0854
Pericardial thickness (median) (mm) 2.4 ± 1.1 (2.1) 2.9 ± 1.9 (2.0) 0.5886*
Chi-square test for independence or Fisher's exact probability, *Mann-Whitney's U testPage 4 of 8
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Comparison of level of B-type natriuretic peptide (BNP) in B group between with and without a history of open-heart surgery (OHS)Figure 1
Comparison of level of B-type natriuretic peptide (BNP) in B group between with and without a history of 
open-heart surgery (OHS). Patients who had a history of OHS had a significantly lower BNP level. The boxes 
represent the 25th, 50th(median), and 75th percentiles, and the whiskers indicate the 10th and 90th percentiles.
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Table 2: Echocardiographic findings
B group NB group p
LAd (median) (mm) 47.5 ± 8.6 (46) 56.5 ± 17.2 (53) 0.0026
IVST (median) (mm) 11.8 ± 2.9 (11) 10.0 ± 2.7 (10) 0.0005
PWT (median) (mm) 11.3 ± 2.5 (11) 10.4 ± 2.6 (10) 0.0225
LVDd (median) (mm) 47.1 ± 5.9 (49) 47.3 ± 6.3 (46) 0.4797
LVDs (median) (mm) 30.5 ± 5.2 (31) 29.6 ± 5.4 (30) 0.1566
EF (median) (%) 65.7 ± 8.5 (66) 67.1 ± 6.8 (67.5) 0.3042
RWT (median) 0.49 ± 0.13 (0.48) 0.44 ± 0.13 (0.42) 0.0114
LVMI (median) (g/m2.7) 73.1 ± 26.1 (70.1) 60.7 ± 24.8 (55.1) 0.0051
E/A (median) 1.3 ± 0.6 (1.2) 1.2 ± 0.5 (1.1) 0.7499
Dct (median) (ms) 213.3 ± 80.4 (185) 235.0 ± 79.4 (230) 0.3367
RVSP (median) (mmHg) 48.2 ± 14.6 (45) 44.7 ± 12.5 (41.5) 0.3035
TR (%) 24 (25) 15 (33) 0.2907*
Mann-Whitney's U test, * Chi-square test for independence or Fisher's exact probability
LAd: left atrial diameters, IVST; interventricular septal thickness, PWT; posterior wall thickness, LVDd: left ventricular end-diastolic diameters, 
LVDs: left ventricular end-systolic diameters, EF: ejection fraction, LVMI: left ventricular mass index, RWT: relative wall thickness, E/A: peak early 
filling velocity to atrial filling velocity ratio, Dct: deceleration time of peak early filling velocity, RVSP: right ventricular systolic pressure, TR: tricuspid 
regurgitation
BMC Cardiovascular Disorders 2009, 9:2 http://www.biomedcentral.com/1471-2261/9/2which may indicate permanent atrial fibrillation and peri-
cardial constriction. Pericardial involvement may be
responsible for HFNEF with less elevated BNP.
Predominant mechanism of BNP release
Brain natriuretic peptide is secreted from the ventricles in
response to increased ventricular wall stress in addition to
myocardial stretch. Because a clear correlation is generally
observed between left ventricular end-diastolic pressure
(LVEDP) and BNP levels, BNP is used in the differential
diagnosis of heart failure [17]. Merisel et al. recommend a
cutoff value of 100 pg/ml of BNP in the diagnosis of heart
failure [5].
However, in constrictive pericarditis, BNP does not
increase despite increases in LVEDP [18]. Therefore, BNP
Comparison of left atrial diameters (LAd) between B group and NB groupFigure 2
Comparison of left atrial diameters (LAd) between B group and NB group. Patients in the NB group who had a his-
tory of open-heart surgery had marked left atrial enlargement. The boxes represent the 25th, 50th (median), and 75th percen-
tiles, and the whiskers indicate the 10th and 90th percentiles.
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Table 3: Multiple logistic regression analysis of factors used for differentiating between patients with elevated BNP and those with less 
elevated BNP
Analysis Predictor Odds Ratio (95% CI) p
Univariate History of open-heart surgery 8.91 (3.98–19.9) < 0.0001
IVST 0.77 (0.66–0.91) 0.0018
LAd 1.06 (1.03–1.10) 0.0005
History of hypertension 0.27 (0.12–0.58) 0.0008
PAC 1.16 (1.05–1.18) 0.0002
Multivariate History of open-heart surgery 3.60 (1.17–11.03) 0.0252
IVST 0.99 (0.80–1.21) 0.8838
LAd 1.02 (0.98–1.07) 0.3743
History of hypertension 0.36 (0.12–1.08) 0.0683
PAC 1.06 (0.99–1.13) 0.1059
The odds ratio reflects the odds for patients with the characteristic in question as compared with those without the characteristic. CI denotes 
confidence interval
LAd; left atrial diameters, IVST; interventricular septal thickness, PAC; plasma aldosteronePage 6 of 8
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constrictive pericarditis from restrictive cardiomyopathy
[10]. During pericardial constriction with no distensibil-
ity, which is caused by factors such as constrictive pericar-
ditis, no increases in transmural pressure are observed
despite increases in intracavity pressure or left ventricular
filling pressure, and myocardial stretch is inhibited [11].
Natriuretic peptide is clinically known to increase follow-
ing pericardiectomy as well as removal of pericardial fluid
[18-21]. Pericardiectomy or pericardiocentesis causes sig-
nificant reductions in intrapericardial pressures, signifi-
cant increases in transmural pressures and wall tension,
and myocardial stretch [19,21]. Thus, natriuretic peptide
secretion is thought to be stimulated by myocardial
stretch resulting from increased transmural pressure,
rather than by increased intracavity pressure [20].
Pericardial adhesion in patients with prior open-heart 
surgery
In developed countries, the most frequent causes of con-
strictive pericarditis are prior cardiac surgery, idiopathic
pericarditis, and irradiation therapy [22]. Pericardial
adhesion, which is commonly observed following OHS,
constitutes a problem during repeat surgery and may be
an extracardiac factor that contributes to heart failure
[22,23]. Because the postoperative patients have a long
postoperative period following pericardiotomy, pericar-
dial stretch is thought to be limited. In these patients,
heart failure may easily become evident due to factors
such as increased heart rate, salt or water loading, renal
dysfunction and infection. The diagnosis of constrictive
pericarditis should be considered in patients presenting
with unexplained right sided heart failure and normal
ejection fraction after cardiac surgery [24].
Atrial degeneration and BNP secretion
B-type natriuretic peptide is also expressed and secreted in
atrial tissue, and is stored in atrial granules along with
ANP [25,26]. BNP also increases in AF and has been
reported to exceed 100 pg/ml [27]. Therefore, the use of
BNP in the differential diagnosis of breathlessness caused
by AF may result in overdiagnosis of heart failure [28]. The
kinetics of atrial-derived BNP in heart failure has not yet
been elucidated. Although ANP increases in AF, it has
been reported to decrease over time, possibly due to
degeneration of atrial muscle [29,30]. ANP and BNP are
structurally similar and are both stored in secretory gran-
ules [31]. In patients with permanent AF and enlarged
atrial size, BNP is thought to decrease in a similar manner
to ANP due to degeneration of atrial tissue. In HFNEF
with a long postoperative period following OHS, espe-
cially valve replacement, the net increase in BNP is
thought to be small due to more permanent AF resulting
in severe atrial damage.
Study Limitations and Perspectives
In the present study, evidence for pericardial lesions was
based only on history of OHS and tendency toward peri-
cardial thickening. Although radiographic determination
of pericardium thickness is often taken into account dur-
ing the assessment of constrictive pericarditis, increased
pericardial thickness dose not necessarily imply constric-
tion. Conversely, constrictive pericarditis can occur in
patients with normal pericardium thickness [23]. It
should not be denied because of normal pericardial thick-
ness demonstrated by radiographic imaging when clini-
cal, echocardiographic, or invasive hemodynamic features
indicate constriction [23].
Hemodynamic assessment using right heart catheteriza-
tion was performed for only two patients. However, non-
compliant patterns, which are regarded as characteristic
findings in constrictive pericarditis, were also observed in
restrictive cardiomyopathies such as right ventricular inf-
arction and amyloidosis, and were thus not a definitive
finding. Furthermore, no characteristic waveforms are
thought to be associated with mild constrictive pericardi-
tis and effusive pericarditis. For the definitive diagnosis of
constrictive pericarditis, it is essential to clarify the pres-
ence of intracardiac and intrathoracic dissociation and the
presence of ventricular discordance. Therefore, constric-
tive pericarditis is often difficult to diagnose requiring
careful attention to detail during measurement of hemo-
dynamics. Eventually, the diagnosis of constrictive peri-
carditis is often confirmed at surgery. Thus, a simple
measurement of BNP may be useful for differentiating
constriction from restriction in HFNEF. Further study is
required to determine the involvement of pericardial
lesions in HFNEF with less elevated BNP.
Conclusion
Acute heart failure with less elevated BNP is associated
with a history of open-heart surgery and marked atrial
enlargement. No association is observed between the level
of BNP and left ventricular function. Atrial degeneration
and an extramyocardial factor, particularly pericardium,
need to be taken into account in the interpretation of the
pathophysiology of heart failure with less elevated BNP.
In a patient suspected of HFNEF, a history of open-heart
surgery (especially mitral prosthesis) is considered diag-
nostic evidence of presence of diastolic heart failure when
plasma levels of BNP are less elevated.
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